论文部分内容阅读
目的探讨通心络胶囊对冠心病患者血清炎症因子以及颈动脉粥样斑块的影响。方法将56例冠心病患者随机均分为通心络治疗组(A组)及常规治疗组(B组)。B组给予常规治疗;A组在常规治疗基础上加用通心络胶囊口服,每次3颗,每日3次,6个月后观察两组患者血清内脏脂肪因子(visfatin)和IL-6以及颈动脉内-中膜厚度(IMT)、颈动脉粥样斑块面积的变化。结果与B组比较,A组治疗6个月后的visfatin和IL-6浓度下降明显[(10.20±0.70)ng/L vs.(9.60±0.77)ng/L和(9.45±0.69)pg/L vs.(9.03±0.81)pg/L](P<0.05)。A组IMT及颈动脉粥样斑块的面积在用药后有降低和减小的趋势,但与B组比较,差异无统计学意义(P>0.05)。结论通心络胶囊可抑制冠心病患者血清visfatin和IL-6的表达,但对颈动脉IMT及颈动脉粥样斑块面积影响不明显。
Objective To investigate the effect of Tongxinluo capsule on serum inflammatory factors and carotid artery plaque in patients with coronary heart disease. Methods 56 cases of coronary heart disease were randomly divided into Tongxinluo treatment group (A group) and conventional treatment group (B group). Group B was given routine treatment. Group A was given Tongxinluo capsule three times a day on the basis of routine treatment, three times a day and six months later. The visfatin and IL-6 And carotid intima-media thickness (IMT), carotid atherosclerotic plaque area changes. Results Compared with group B, the concentrations of visfatin and IL-6 in group A decreased significantly after 6 months treatment [(10.20 ± 0.70) ng / L vs. (9.60 ± 0.77) ng / L and (9.45 ± 0.69) pg / L vs. (9.03 ± 0.81) pg / L] (P <0.05). The area of IMT and carotid artery plaque in group A decreased and decreased after treatment, but there was no significant difference between group A and group B (P> 0.05). Conclusion Tongxinluo capsule can inhibit the expression of serum visfatin and IL-6 in patients with coronary heart disease, but has no obvious effect on carotid IMT and carotid plaque area.